Takeki Uehara

5.2k total citations · 3 hit papers
86 papers, 3.6k citations indexed

About

Takeki Uehara is a scholar working on Epidemiology, Molecular Biology and Cancer Research. According to data from OpenAlex, Takeki Uehara has authored 86 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Epidemiology, 28 papers in Molecular Biology and 16 papers in Cancer Research. Recurrent topics in Takeki Uehara's work include Influenza Virus Research Studies (17 papers), Respiratory viral infections research (16 papers) and Liver Disease Diagnosis and Treatment (15 papers). Takeki Uehara is often cited by papers focused on Influenza Virus Research Studies (17 papers), Respiratory viral infections research (16 papers) and Liver Disease Diagnosis and Treatment (15 papers). Takeki Uehara collaborates with scholars based in Japan, United States and Australia. Takeki Uehara's co-authors include Takao Shishido, Kenji J. Tsuchiya, Ivan Rusyn, Keiko Kawaguchi, Frederick G. Hayden, Tetsuro Urushidani, Simon Portsmouth, Atsushi Ono, Igor P. Pogribny and Mikinori Torii and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Scientific Reports.

In The Last Decade

Takeki Uehara

84 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents

2018 595 citations Frederick G. Hayden, Nobuo Hirotsu et al. profile →
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil

2018 312 citations Shinya Omoto, Takashi Hashimoto et al. Scientific Reports profile →
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19

2024 46 citations Hiroshi Yotsuyanagi, Norio Ohmagari et al. profile →

Peers

Takeki Uehara

EPIDE

CTM

Lena E. Friberg Sweden

Jian‐Dong Jiang China

Rex A. Parker United States

Michel Tod France

Sudeep Pushpakom United Kingdom

Jin‐Ching Lee Taiwan

Wu Zhong China

Zifeng Yang China

Jian Lin China

Adrian S. Ray United States

Lena E. Friberg Sweden

Takeki Uehara

1.4k ×0.9

EPIDE

1.1k ×0.9

533 ×0.7

159 ×0.4

CTM

359 ×0.9

Citations per year, relative to Takeki Uehara Takeki Uehara (= 1×) peers Lena E. Friberg

Countries citing papers authored by Takeki Uehara

Since Specialization

Citations

This map shows the geographic impact of Takeki Uehara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takeki Uehara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takeki Uehara more than expected).

Fields of papers citing papers by Takeki Uehara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takeki Uehara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takeki Uehara. The network helps show where Takeki Uehara may publish in the future.

Co-authorship network of co-authors of Takeki Uehara

This figure shows the co-authorship network connecting the top 25 collaborators of Takeki Uehara. A scholar is included among the top collaborators of Takeki Uehara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takeki Uehara. Takeki Uehara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yotsuyanagi, Hiroshi, Norio Ohmagari, Yohei Doi, et al.. (2024). Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial. Antiviral Research. 229. 105958–105958. 8 indexed citations

Takazono, Takahiro, Yuki Yoshida, Masahiro Kinoshita, et al.. (2024). Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19. Infectious Diseases and Therapy. 13(8). 1821–1833. 11 indexed citations

Ohmagari, Norio, Hiroshi Yotsuyanagi, Yohei Doi, et al.. (2024). Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID‐19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial. Influenza and Other Respiratory Viruses. 18(6). e13338–e13338. 6 indexed citations

Yotsuyanagi, Hiroshi, Norio Ohmagari, Yohei Doi, et al.. (2023). A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part). Medicine. 102(8). e33024–e33024. 29 indexed citations

Hirotsu, Nobuo, Hiroki Sakaguchi, Keita Fukao, et al.. (2023). Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan. BMC Pediatrics. 23(1). 35–35. 8 indexed citations

Mukae, Hiroshi, Hiroshi Yotsuyanagi, Norio Ohmagari, et al.. (2022). Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. Clinical Infectious Diseases. 76(8). 1403–1411. 90 indexed citations

Lee, Leo, Jie Zhou, Rebecca Frise, et al.. (2021). Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model. PLoS Pathogens. 17(5). e1009527–e1009527. 29 indexed citations

Lee, Leo, Jie Zhou, Rebecca Frise, et al.. (2020). Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission. PLoS Pathogens. 16(4). e1008395–e1008395. 31 indexed citations

Ison, Michael G., Simon Portsmouth, Yuki Yoshida, et al.. (2020). Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases. 20(10). 1204–1214. 166 indexed citations

10.

Watanabe, Akira, Tadashi Ishida, Nobuo Hirotsu, et al.. (2019). Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study. Antiviral Research. 163. 75–81. 22 indexed citations

11.

Dweep, Harsh, Yuji Morikawa, Binsheng Gong, et al.. (2017). Mechanistic roles of microRNAs in hepatocarcinogenesis: A study of thioacetamide with multiple doses and time-points of rats. Scientific Reports. 7(1). 3054–3054. 6 indexed citations

12.

Furuya, Shinji, Grace A. Chappell, Yasuhiro Iwata, et al.. (2016). A mouse model of alcoholic liver fibrosis-associated acute kidney injury identifies key molecular pathways. Toxicology and Applied Pharmacology. 310. 129–139. 16 indexed citations

13.

Uehara, Takeki, Yuji Morikawa, Ko Omura, et al.. (2014). miRNA expression atlas in male rat. Scientific Data. 1(1). 140005–140005. 50 indexed citations

14.

Uehara, Takeki, Oksana Kosyk, Emmanuelle Jeannot, et al.. (2012). Acetaminophen-induced acute liver injury in HCV transgenic mice. Toxicology and Applied Pharmacology. 266(2). 224–232. 11 indexed citations

15.

Minowa, Yohsuke, Chiaki Kondo, Takeki Uehara, et al.. (2012). Toxicogenomic multigene biomarker for predicting the future onset of proximal tubular injury in rats. Toxicology. 297(1-3). 47–56. 27 indexed citations

16.

Uehara, Takeki, Yohsuke Minowa, Yuji Morikawa, et al.. (2011). Prediction model of potential hepatocarcinogenicity of rat hepatocarcinogens using a large-scale toxicogenomics database. Toxicology and Applied Pharmacology. 255(3). 297–306. 69 indexed citations

17.

Tonomura, Yutaka, Noriko Tsuchiya, Mikinori Torii, & Takeki Uehara. (2010). Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. Toxicology. 273(1-3). 53–59. 55 indexed citations

18.

Bradford, Blair U., Eric F. Lock, Oksana Kosyk, et al.. (2010). Interstrain Differences in the Liver Effects of Trichloroethylene in a Multistrain Panel of Inbred Mice. Toxicological Sciences. 120(1). 206–217. 48 indexed citations

19.

Powell, Christine L., Blair U. Bradford, Christopher P. Craig, et al.. (2010). Mechanism for Prevention of Alcohol-Induced Liver Injury by Dietary Methyl Donors. Toxicological Sciences. 115(1). 131–139. 28 indexed citations

20.

Uehara, Takeki, Atsushi Ono, Toshiyuki Maruyama, et al.. (2009). The Japanese toxicogenomics project: Application of toxicogenomics. Molecular Nutrition & Food Research. 54(2). 218–227. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact